BioNexus Gene Lab Corp Files 8-K

TL;DR

BioNexus Gene Lab Corp filed an 8-K on Oct 20, 2025, with financial docs.

AI Summary

BioNexus Gene Lab Corp. filed an 8-K on October 23, 2025, reporting events as of October 20, 2025. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. The company is incorporated in Wyoming and its principal executive offices are located in Kuala Lumpur.

Why It Matters

This 8-K filing indicates routine corporate disclosures and the submission of financial documents, providing transparency to investors about the company's operational and financial status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

• BioNexus Gene Lab Corp. (company) — Filer
• October 20, 2025 (date) — Earliest event reported
• October 23, 2025 (date) — Filing date
• Wyoming (jurisdiction) — State of Incorporation
• Kuala Lumpur (location) — Principal executive offices

FAQ

Filing Documents

• bglc_8k.htm (8-K) — 26KB
• bglc_ex991.htm (EX-99.1) — 12KB
• 0001477932-25-007708.txt ( ) — 158KB
• bglc-20251020.xsd (EX-101.SCH) — 5KB
• bglc-20251020_lab.xml (EX-101.LAB) — 15KB
• bglc-20251020_cal.xml (EX-101.CAL) — 1KB
• bglc-20251020_pre.xml (EX-101.PRE) — 9KB
• bglc-20251020_def.xml (EX-101.DEF) — 2KB
• bglc_8k_htm.xml (XML) — 4KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On October 20, 2025, BioNexus Gene Lab Corp (the "Company" or "BGLC") issued a press release announcing that it had entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. ("Birch"), a Canadian biotechnology company developing regenerative treatments for organ fibrosis, topical scarring, and autoimmune diseases. The Term Sheet outlines the principal terms of a proposed collaboration under which BGLC would lead Birch's current financing round through a strategic equity investment and joint commercialization of Birch's FS2 (kynurenic acid) topical platform in Southeast Asia. The Term Sheet is non-binding and intended solely as a framework for continued discussions. There can be no assurance that a definitive agreement will be executed or that the proposed transactions will be completed on the terms contemplated or at all. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

01. Financial Statement and Exhibits

Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 20, 2025, announcing execution of the Strategic Partnership Term Sheet with Birch BioMed Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. /s/ Su-Leng Tan Lee By: Su-Leng Tan Lee Chief Executive Officer Date: October 23, 2025 3

View Full Filing

View this 8-K filing on SEC EDGAR